GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 180 Life Sciences Corp (NAS:ATNF) » Definitions » Shareholder Yield %

ATNF (180 Life Sciences) Shareholder Yield % : -13.57% (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is 180 Life Sciences Shareholder Yield %?

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, 180 Life Sciences's Shareholder Yield % was -13.57%.


180 Life Sciences Shareholder Yield % Historical Data

The historical data trend for 180 Life Sciences's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

180 Life Sciences Shareholder Yield % Chart

180 Life Sciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Shareholder Yield %
- - 1.75 3.32 14.26

180 Life Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.50 14.26 9.60 10.03 -34.43

Competitive Comparison of 180 Life Sciences's Shareholder Yield %

For the Biotechnology subindustry, 180 Life Sciences's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


180 Life Sciences's Shareholder Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 180 Life Sciences's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where 180 Life Sciences's Shareholder Yield % falls into.



180 Life Sciences Shareholder Yield % Calculation

180 Life Sciences's Shareholder Yield % for the quarter that ended in Sep. 2024 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0 %+0 %+-34.43 %
=-34.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


180 Life Sciences  (NAS:ATNF) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


180 Life Sciences Shareholder Yield % Related Terms

Thank you for viewing the detailed overview of 180 Life Sciences's Shareholder Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


180 Life Sciences Business Description

Traded in Other Exchanges
N/A
Address
3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA, USA, 94306
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
Executives
James N. Woody director, officer: Chief Executive Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Marc Feldmann director 5 DURHAM TERRACE, LONDON X0 W25PB
Lawrence Steinman director 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Mcgovern Jr. Donald A. director C/O CARS.COM, 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Quan Anh Vu officer: COO / Chief Business Officer 22616 ERWIN STREET, WOODLAND HILLS CA 91367
Ozan Pamir officer: Interim CFO 2443 FILLMORE ST #380-17649, SAN FRANCISCO CA 94115
Pamela G Marrone director C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, A-107, DAVIS CA 95618
Teresa Deluca director 40 BURTON HILLS BOULEVARD, SUITE 500, NASHVILLE TN 37215
Russell T Ray director 2525 DUPONT DR, IRVINE CA 92612
Knuettel Ii Francis director 205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701
Marlene Krauss director, 10 percent owner, officer: Chief Executive Officer C/O KBL HEALTHCARE INC, 645 MADISON AVE, NEW YORK NY 10022
Lawrence Marshall Gold director 830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025
Jonathan B. Rothbard officer: Chief Scientific Officer 501 BEALE STREET, UNIT 8D, SAN FRANCISCO CA 94105
Shoshana Shendelman director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Richard W Barker director 290 COMMONWEALTH AVENUE #17, BOSTON MA 02115

180 Life Sciences Headlines

From GuruFocus

180 Life Sciences Announces Presentation at the Gordon Conference

By sperokesalga sperokesalga 02-27-2023